- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03883711
Acute Myocardial Infarction: Prognostic and Therapeutic Evaluation (AMIPE)
Acute Myocardial Infarction From Clinical Presentation to Strategy Treatment
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
AMIPE is an observational, multicenter and both retrospective and prospective study enrolling a cohort of consecutive incident patients admitted to participating hospitals with a diagnosis of acute coronary syndrome or myocardial injury from 01/01/2016 to 31/12/2023.
The aim of this study is to create a database including a comprehensive characterization of these patients in order to obtain new scientific evidence about these conditions. Informations about the patients will be gathered from in-hospital medical records. A written informed consent is needed for every prospective patients enrolled in the study,
In particular, the main objectives of the study are:
- document the characteristics of all patients presenting with acute coronary syndrome and myocardial injury;
- document the long term outcome rates;
- document the therapeutic regimens and investigation conformity of treatment with already established guidelines.
Every diagnostic or therapeutic intervention will be in accordance with established guidelines and good clinical practice.
Statistics will be conducted utilizing univariate and multivariate analysis for outcomes. In particular for what concerns univariate analysis, ordinal variables will be analysed with t-test and Mann-Whitney Test, whereas categorical responses with Fischer Exact Test and with Pearson Chi-square test.
Multivariate analysis will be conducted with logistic regression for dichotomous variables, with mixed generalized linear model for ordinal or nominal variables and with ANOVA or MANOVA for continuous variables.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Carmine Pizzi, Dr
- Phone Number: 0039 (0)512144933
- Email: carmine.pizzi@unibo.it
Study Locations
-
-
-
Bologna, Italy, 40138
- Recruiting
- Policlinico Sant'Orsola-Malpighi, Cardiology Department
-
Contact:
- Carmine Pizzi, Dr
- Phone Number: 0039 (0)512144933
- Email: carmine.pizzi@unibo.it
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient aged > 18 years old
- Acute coronary syndrome or myocardial injury
- Written informed consent
Exclusion Criteria:
- under age or not able to give informed consent
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients with acute coronary syndrome or myocardial injury
Incident consecutive patients presenting with acute coronary syndrome or myocardial injury
|
Create a database containing clinical characteristic, clinical presentation, flow indexes and treatment of consecutive incident patients with ACS or myocardial injury.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All cause mortality
Time Frame: 1 year
|
Death rate
|
1 year
|
All cause mortality
Time Frame: 3 years
|
Death rate
|
3 years
|
All cause mortality
Time Frame: 5 years
|
Death rate
|
5 years
|
Major Adverse Cardiac Events (MACEs)
Time Frame: 1 year
|
MACEs rate
|
1 year
|
Major Adverse Cardiac Events (MACEs)
Time Frame: 3 years
|
MACEs rate
|
3 years
|
Major Adverse Cardiac Events (MACEs)
Time Frame: 5 years
|
MACEs rate
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cardiovascular risk factors prevalence
Time Frame: 1 year
|
Differences in percentage of patients with STEMI or NSTEMI, or type 1 or type 2 myocardial infarction with any risk factors
|
1 year
|
Cardiovascular risk factors prevalence
Time Frame: 3 year
|
Differences in percentage of patients with STEMI or NSTEMI, or type 1 or type 2 myocardial infarction with any risk factors
|
3 year
|
Cardiovascular risk factors prevalence
Time Frame: 5 year
|
Differences in percentage of patients with STEMI or NSTEMI, or type 1 or type 2 myocardial infarction with any risk factors
|
5 year
|
Differences in clinical presentation
Time Frame: 3 year
|
Prevalence of patients presenting with ST elevation, angina, dyspnea, atypical chest pain, cardiogenic shock, arrhytmias)
|
3 year
|
Differences in clinical presentation
Time Frame: 1 year
|
Prevalence of patients presenting with ST elevation, angina, dyspnea, atypical chest pain, cardiogenic shock, arrhytmias)
|
1 year
|
Differences in clinical presentation
Time Frame: 5 year
|
Prevalence of patients presenting with ST elevation, angina, dyspnea, atypical chest pain, cardiogenic shock, arrhytmias)
|
5 year
|
Difference diagnosis between myocardial infarction subtypes and between myocardial infarction and myocardial injury
Time Frame: 5 year
|
Differences in clinical presentation (ST elevation, angina, dyspnea, atypical chest pain, cardiogenic shock, arrhytmias)
|
5 year
|
Differences in flow characteristics
Time Frame: 1 year
|
TIMI, TIMI frame count
|
1 year
|
Differences in flow characteristics
Time Frame: 3 year
|
TIMI, TIMI frame count
|
3 year
|
Differences in flow characteristics
Time Frame: 5 year
|
TIMI, TIMI frame count
|
5 year
|
Differences and impact of periprocedural ischemic complications
Time Frame: 5 year
|
Type 4a myocardial infarction, periprocedural myocardial injury
|
5 year
|
Collaborators and Investigators
Investigators
- Principal Investigator: Carmine Pizzi, Dr, University of Bologna, Cardiology Department
Publications and helpful links
General Publications
- Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD; Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018 Nov 13;138(20):e618-e651. doi: 10.1161/CIR.0000000000000617. No abstract available. Erratum In: Circulation. 2018 Nov 13;138(20):e652.
- Bonaca MP, Wiviott SD, Braunwald E, Murphy SA, Ruff CT, Antman EM, Morrow DA. American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38). Circulation. 2012 Jan 31;125(4):577-83. doi: 10.1161/CIRCULATIONAHA.111.041160. Epub 2011 Dec 23.
- Sandoval Y, Smith SW, Sexter A, Thordsen SE, Bruen CA, Carlson MD, Dodd KW, Driver BE, Hu Y, Jacoby K, Johnson BK, Love SA, Moore JC, Schulz K, Scott NL, Apple FS. Type 1 and 2 Myocardial Infarction and Myocardial Injury: Clinical Transition to High-Sensitivity Cardiac Troponin I. Am J Med. 2017 Dec;130(12):1431-1439.e4. doi: 10.1016/j.amjmed.2017.05.049. Epub 2017 Jul 21.
- Baron T, Hambraeus K, Sundstrom J, Erlinge D, Jernberg T, Lindahl B; TOTAL-AMI study group. Type 2 myocardial infarction in clinical practice. Heart. 2015 Jan;101(2):101-6. doi: 10.1136/heartjnl-2014-306093. Epub 2014 Oct 20.
- Paolisso P, Foa A, Bergamaschi L, Angeli F, Fabrizio M, Donati F, Toniolo S, Chiti C, Rinaldi A, Stefanizzi A, Armillotta M, Sansonetti A, Magnani I, Iannopollo G, Rucci P, Casella G, Galie N, Pizzi C. Impact of admission hyperglycemia on short and long-term prognosis in acute myocardial infarction: MINOCA versus MIOCA. Cardiovasc Diabetol. 2021 Sep 24;20(1):192. doi: 10.1186/s12933-021-01384-6.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 600/2018/Oss/AOUBo
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Coronary Syndrome
-
Yonsei UniversityRecruitingCoronary Artery Disease, Acute Coronary SyndromeKorea, Republic of
-
Meditrix CorpNational University of Ireland, Galway, Ireland; Boston Scientific Japan K.K.; Fujita Health UniversityRecruitingChronic Coronary Syndrome | Non ST Segment Elevation Acute Coronary SyndromeJapan, Ireland
-
OrbusNeichDuke Clinical Research Institute; OrbusNeich Medical K.K.CompletedCoronary Arteriosclerosis | Non ST Segment Elevation Acute Coronary SyndromeUnited States, Japan
-
Medical University of WarsawRecruitingAcute Coronary Syndrome | Chronic Coronary Syndrome | Non ST Segment Elevation Acute Coronary SyndromePoland
-
Niguarda HospitalCompletedAcute Coronary Syndrome With ST Elevation on Electrocardiogram | Acute Coronary Syndrome Without ST Elevation on Electrocardiogram | Noncritical Coronary Artery Disease Coronary Stenosis Less Than 50 Per Cent | Aortic AneurysmsItaly
-
Sohag UniversityRecruitingLeft Main Coronary Artery Disease With Acute Coronary SyndromeEgypt
-
Eli Lilly and CompanyDaiichi Sankyo, Inc.CompletedCoronary Arteriosclerosis | Acute Coronary SyndromesUnited States
-
University of PatrasCompletedCoronary Artery Disease (CAD) | Acute Coronary Syndrome (ACS)Greece
-
The First Affiliated Hospital with Nanjing Medical...Unknown
-
Yonsei UniversityCompletedAcute Coronary Syndrome (ACS)Korea, Republic of
Clinical Trials on Database
-
King Faisal Specialist Hospital & Research CenterUnknownLymphoma, Non-Hodgkin | Hodgkin DiseaseSaudi Arabia
-
King Faisal Specialist Hospital & Research CenterUnknown
-
King Faisal Specialist Hospital & Research CenterUnknownLymphoma, Non-Hodgkin | Hodgkin DiseaseSaudi Arabia
-
RWTH Aachen UniversityRecruitingIntensive Care in GeneralGermany
-
King Faisal Specialist Hospital & Research CenterUnknownLeukemia, Myeloblastic, Acute
-
Centre Hospitalier Universitaire, AmiensWithdrawn
-
King Faisal Specialist Hospital & Research CenterUnknownAcute Lymphocytic LeukemiaSaudi Arabia
-
King Faisal Specialist Hospital & Research CenterUnknownAplastic Anemia and Other Marrow Failure SyndromeSaudi Arabia
-
King Faisal Specialist Hospital & Research CenterCompletedBreast CancerSaudi Arabia
-
GlaxoSmithKlineCompletedRotavirus Gastroenteritis | Nosocomial Rotavirus Gastroenteritis